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ABSTRACT
Background: Anthocyanin-rich blueberry intake is associated with
reduced type 2 diabetes and cardiovascular disease (CVD) risk in
prospective studies, although long-term randomized controlled trials
(RCTs) have not been conducted in at-risk populations.
Objective: In the longest-duration RCT to date, we examined
the effect of 6-mo blueberry intake on insulin resistance and
cardiometabolic function in metabolic syndrome.
Methods: A double-blind, parallel RCT (n = 115; age 63 ± 7 y;
68% male; body mass index 31.2 ± 3.0 kg/m2) was conducted,
which fed 2 dietarily achievable blueberry intakes [equivalent to 1/2
and 1 cup/d (75/150 g)] compared with matched placebo. Insulin
resistance was assessed via the homeostasis model assessment of
insulin resistance (primary endpoint) and confirmed by [6-6-2H2]-
glucose-labeled, 2-step hyperinsulinemic clamp (n = 20). Clinically
relevant cardiometabolic endpoints [including flow-mediated dilata-
tion, augmentation index, lipoprotein status (by nuclear magnetic
resonance spectroscopy), and nitric oxide (NO)-related metabolite
assay] and anthocyanin metabolism were assessed.
Results: A daily intake of 1 cup of blueberries improved endothelial
function (flow-mediated dilatation: +1.45%; 95% CI: 0.83%, 2.1%;
P = 0.003), systemic arterial stiffness (augmentation index: –
2.24%; 95% CI: –3.97%, –0.61%; P = 0.04) and attenuated
cyclic guanosine monophosphate concentrations. In statin nonusers
(n = 71), elevated high-density lipoprotein cholesterol (+0.08
mmol/L; P = 0.03), high-density lipoprotein particle density
(+0.48n, ×10–6; P = 0.002) and apolipoprotein A-I (+0.05 g/L;
P = 0.01) concentrations were observed following the 1-cup/d
intervention. Treatment compliance was 94.1% (wrapper returns)
and total concentrations of anthocyanin-derived phenolic acid
metabolites significantly increased, dose-dependently, in serum and
24-h urine (P< 0.01 and P< 0.001, respectively). Insulin resistance,
pulse wave velocity, blood pressure, NO, and overall plasma thiol
status were unaffected. Likewise, a half cup per day had no effect on
any biomarkers.
Conclusions: Despite insulin resistance remaining unchanged we
show, to our knowledge, the first sustained improvements in vascular
function, lipid status, and underlying NO bioactivity following 1
cup blueberries/d. With effect sizes predictive of 12–15% reductions
in CVD risk, blueberries should be included in dietary strategies
to reduce individual and population CVD risk. This study was
registered at clinicaltrials.gov as NCT02035592. Am J Clin Nutr
2019;109:1535–1545.
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Introduction
Metabolic syndrome (MetS) affects approximately one-third
of Westernized populations and has been widely reported to
increase the risk of type 2 diabetes, cardiovascular (CV) disease,
and CV-related mortality. Although insulin resistance is consid-
ered central to the development of MetS, compromised vascular
function and dysregulated lipids are integral in the etiology,
and worsening, of the condition. The clinical management of
MetS is initially through lifestyle modifications, with statins and
antihypertensive medications added to ongoing lifestyle guid-
ance as MetS severity increases (1). Consequently, identifying
effective dietary approaches has clinical relevance throughout
MetS progression—as a preventive strategy in nonmedicated
individuals, and as an adjunct to those receiving standard
pharmacologic therapies.
Blueberries and their main bioactive constituents (especially
the flavonoid subclass, anthocyanins) have been identified as
candidates to improve CV-related endpoints and the components
of MetS. Specifically, prospective studies have shown that higher
anthocyanin intakes are associated with lower all-cause mortality
(2) and reduced risk of type 2 diabetes (3) and myocardial
infarction (4, 5); with benefits also observed for biomarkers
including reduced insulin resistance (6) and hypertension (7)
and lower weight gain (8). Notably, blueberry intake (ranging
from >1 to 3 portions/wk) has been independently associated
with many of these benefits (2–4, 8). Major limitations, however,
remain with the available randomized controlled trial (RCT)
evidence, with blueberry studies being either single-dose/acute
interventions (9–12) or short-duration trials (≤8 wk (13–19)),
or having provided intakes [e.g., 300 g fresh weight (12), or
45–50 g freeze-dried blueberries/d (16, 17)] that are unlikely
to be sustainable in the longer term. Although single-portion
studies (10, 11) and continuous feeding over 6–8 wk (13, 16–
18) has shown encouraging improvements in vascular function,
not all studies report positive vascular outcomes (12, 20), and the
effect of blueberry intake on insulin resistance remains equivocal
(16, 17).
We investigated the effects of 6-mo blueberry intake (at 2
dietarily achievable levels) on biomarkers of insulin resistance,
vascular function, lipid status, and anthocyanin metabolism in
adults with MetS.
Methods
Study design and participant population
A double-blind, placebo-controlled, parallel study was con-
ducted that enrolled overweight and obese (BMI ≥25 kg/m2)
adults, aged 50–75 y, with MetS [≥3 MetS components,
i.e., impaired fasting glucose, hypertension, central adiposity,
hypertriglyceridemia, and low levels of HDL cholesterol (21)], to
take part in a 6-mo dietary intervention. Ineligibility included≤2
MetS components and criteria relating to disease status, lifestyle
choices, medication, and supplement use (described in the
Supplemental Methods), including recent, past, or present
smoking history; diabetes, vascular disease, cancer, or diges-
tive, hepatic, or renal disorders; and prescribed hypoglycemic,
vasodilator, or hormone-replacement medications. Those with
untreated hypertension were excluded at screening. Antihyper-
tensive or statin therapies (or a combination) were permissible
following habituation (i.e., antihypertensive medication, ≥6 mo;
statins, ≥3 mo).
In total, 138 eligible participants were randomly assigned to
1 of 3 treatment groups, consisting of 2 dietarily achievable
blueberry intakes (equivalent to 1 and 1/2 US cup of fresh
blueberries per day: 150 and 75 g, respectively) and placebo.
AR2007 adaptive random-sequence allocation software (22)
was utilized, which incorporated 4 balancing strata that were
considered likely a priori to affect insulin resistance and vascular
function: sex, number of MetS criteria, age, and statin/blood
pressure (BP) medication use. The randomization procedure is
further described in Supplemental Methods and allocation to
treatment shown in Figure 1A. Following a 21-d run-in period
of dietary restrictions, insulin resistance and cardiometabolic
endpoints were assessed at baseline and 6-mo after intervention
(study intervention flow shown in Figure 1B). A substudy
of peripheral and hepatic insulin sensitivity was conducted
on 20 consenting participants from the main study (Figure
1C), n = 10 from each of the 1-cup blueberry and placebo
groups.
The primary outcome was change ( 0 to 6 mo) in insulin
resistance (HOMA-IR). Change ( 0 to 6 mo) in vascular
function [flow-mediated dilatation (FMD), augmentation index
(AIx), carotid-to-femoral pulse wave velocity (cfPWV), and
BP], biomarkers of cardiometabolic health [lipid status, nitric
oxide (NO) intermediates, glycated hemoglobin (HbA1c), and
glucose], and blueberry metabolites were secondary outcomes.
The study was approved by the National Research Ethics
Committee (East of England) and was conducted between
January 2014 and November 2016 at 2 UK Clinical Research
Facilities (CRFs): University of East Anglia CRF, and the
NIHR/Wellcome Trust CRF (Cambridge University). The study
was registered at www.clinicaltrials.gov as NCT02035592,
followed the principles of the Declaration of Helsinki of 1975,
as revised in 1983, and participants gave written consent before
enrollment.
Intervention products and compliance
In this study, participants were required to consume the
intervention product daily for 6 mo. The 3 types of intervention
foods (equivalent to 1 and 1/2 US cup blueberries, and
placebo) were isocaloric and carbohydrate-matched (glucose
31%, fructose 30%, sucrose 0%), and provided in milled, freeze-
dried powder form as follows: 26 g freeze-dried blueberries (1
cup), a hybrid treatment combining 13 g freeze-dried blueberries
and 13 g placebo material (1/2 cup), and 26 g placebo (produced
by the US National Food Lab). The placebo material’s main
ingredients were dextrose, maltodextrin, and fructose, which
were produced as a purple powder, with blueberry aromatics
generated from natural (nonanthocyanin) and artificial color and
flavorings. Prior to the study initiation, treatments were tested to
be of similar appearance (i.e., color and texture) and matched for
taste. Treatment identity was masked by providing all treatments
in opaque, 26-g single-serve sachets. Blueberries were from the
same harvest (produced by the US Highbush Blueberry Council)
and the 1-cup, 1/2-cup, and placebo treatments contained
364, 182, and 0 mg anthocyanin, and 879, 439, and 0 mg
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FIGURE 1 Flow chart of study participants and intervention conduct. (A) Recruitment and retention in the study. (B) An overview of the study involvement
for each participant. (C) The flow of study participants in the hyperinsulinemic euglycemic clamp substudy. 1 cup = 150 g blueberries. MetS, metabolic
syndrome; SAE, serious adverse event; PE, physical examination.
phenolics, respectively (levels independently verified in-house).
These anthocyanin doses have previously been shown to acutely
improve endothelial function (10).
Participants were instructed to consume 1 sachet per d, with 8
standardized recipe ideas provided; these encompassed creating
a “blueberry” drink or smoothie, adding the powder to cereals or
to yoghurt/desserts, incorporation with banana toast, or adding
to salads (top dressing, or within a vinaigrette). The intake
method was not prescriptive, to allow participants to incorporate
their daily intake into a variety of foods over this extended, 6-
mo intervention. Compliance with intervention product intake
was calculated from returned wrappers and unused sachets,
and the effectiveness of participant blinding was assessed by
questionnaire at 6 mo.
Dietary and lifestyle restrictions
For 21 d prior to, and throughout, the 6-mo study, dietary
restrictions were implemented to limit anthocyanin intake
(including blueberry abstinence and limits of 1 portion/wk
for anthocyanin-rich foods) and other foods known to modify
vascular function (see Supplemental Table 1 and Supplemental
Methods for details). Before each assessment visit, strenuous
exercise was avoided for 48 h and anthocyanin-rich or nitrate-
/nitrite-rich foods, caffeine, and alcohol were avoided for 24 h
(see Supplemental Table 2). Additionally, low-nitrite/-nitrate
bottled water (consumed for 24 h) and a standardized evening
meal (anthocyanin-free and low in flavonoids; consumed prior
to overnight fasting) was provided. A 131-item validated food-
frequency questionnaire (FFQ) (23) was repeated throughout the
study (baseline, interim, 6 mo) to monitor adherence to dietary
guidance.
Assessment of insulin resistance and sensitivity, vascular
function, and anthropometry
Insulin resistance and insulin sensitivity were calculated from
fasting insulin and glucose concentrations through the use of
the HOMA-IR calculation and the quantitative insulin sensitivity
index (QUICKI), according to standard equations (24, 25). At
a separate visit, the 2-step hyperinsulinemic euglycemic clamp
substudy was performed at the Cambridge University Hospital
CRF as previously described (26); see Supplemental Methods for
details of the assessment protocol.
Triplicate BP measurements were taken (separated by 3 min)
with an automated sphygmomanometer (Omron 705IT; Omron
Healthcare Co.), following 15 min of supine rest in a quiet,
temperature-monitored clinical room (21–24◦C). Subsequently,
3-lead electrocardiogram gated brachial artery FMD was as-
sessed by ultrasound (Philips iE33; 11–13MHz linear transducer;
Philips) following a standardized procedure: 1 min baseline, 5
min reactive hyperemia (via 220 mmHg sphygmomanometric
cuff inflation), 5 min postocclusion (following cuff deflation).
Image acquisition and automated edge-detection analysis were
performed with commercial software (Vascular Imager and
Brachial Analyzer version 5, respectively; Medical Imaging Ap-
plications LLC) and percentage FMD (%FMD) was calculated as
(diametermax − diameterbaseline)/diameterbaseline × 100. A detailed
description of the assessment protocol can be found in the
Supplemental Methods.
Aortic distensibility was assessed via cfPWV and systemic
arterial stiffness (standardized to a heart rate of 75) was assessed
via the AIx (a measure of the wave reflection to arterial pressure
waveforms) (both Vicorder, Smart Medical) as previously
described (27);≤6 assessments were made with a target of≤10%
coefficient of variation. Duplicate anthropometric measures (i.e.,
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body weight, height, and waist and hip circumference) were
taken. An identical sequence of assessments were performed at
baseline and 6 mo.
Laboratory measurements
After an overnight fast (≥10 h), venous blood was collected
and centrifuged, and plasma and serum aliquots were then stored
at –80◦C. Cardiometabolic biomarkers and anthocyanin/phenolic
metabolite concentrations were quantified.
Fasting serum insulin was measured by ELISA (Mercodia)
according to the manufacturer’s instructions. Fasting glucose, as
well as the lipoproteins, i.e., total cholesterol, HDL cholesterol
and triglycerides (TGs), were assessed with the use of a clinical
chemistry autoanalyzer (ARCHITECT c; Abbott Laboratories)
and concentrations of HbA1c were assessed by boronate infinity
chromatography (Menarini Hb 9210); both at the Norfolk &
Norwich University Hospital. The Friedewald equation (28) was
used to calculate LDL cholesterol. To explore the mechanisms
underlying the altered lipid and lipoprotein profiles, HDL
particle number (HDL-P, n), LDL particle number (LDL-P, n),
apolipoprotein A-I (apoA-I), and apolipoprotein B (apoB) were
measured by nuclear magnetic resonance (NMR) spectroscopy
(Nightingale Health). Similarly, to evaluate the mechanisms
underlying changes in vascular function, plasma nitrite (NO2−),
nitrate (NO3−), and total nitroso species (RXNO) were measured
by ion chromatography and gas-phase chemiluminescence assay
(29). Total free thiols were assessed spectrophotometrically
following reaction with Ellman’s reagent (30). Cyclic guanosine
monophosphate (cGMP) was measured by enzyme immunoas-
say (KGE003; RnD Systems). The intra-assay coefficients of
variation were 2.2% (HbA1c), 1.51% (glucose), 0.86% (total
cholesterol), 2.91% (HDL cholesterol), 1.23% (TGs), 11.8%
(insulin), 1.6% (NO2−), 16.2% (NO3−), 15% (RXNO), 10%
(total free thiols), and 9.9% (cGMP). The analytical success rate
for NMR assessments were 99.6% for apoA-I and apoB and
100% for HDL-P and LDL-P.
In the clamp substudy, fasting plasma insulin (7.65% co-
efficient of variation) was measured by chemiluminescence
immunoassay (Liaison XL model; Diasorin) and plasma nones-
terified fatty acid (7.3% coefficient of variation) was assessed
by enzymatic colorimetric assay (Roche) (both at Cambridge
University Hospitals, Cambridge, UK).
Anthocyanin-derived phenolic metabolite analysis
Quantification of anthocyanin-derived phenolic acids in serum
and 24-h urine samples was performed on an 1200 Agilent
HPLC coupled to a SCIEX 3200 Q-trap electrospray ionization
tandem mass spectrometer (SCIEX), according to our previously
published method (31) with further optimization to include
previously reported phenolic metabolites. In total, 72 metabolites
were quantified from 3 unique scheduled multiple reaction
monitoring methods. A full description can be found in the
Supplemental Methods and in Supplemental Table 3.
Statistical analysis
The study sample size was based on a previously reported
insulin resistance response following a 6-mo dietary intervention
in obese participants (32). A sample size of 117 participants
was anticipated to detect a 25% reduction in HOMA-IR (SD
1.1, 90% power, α 0.05); this was increased to 144 participants
(n = 48/group, allowing recruitment of 24 males/females per
group), which accounted for an anticipated ∼20% dropout rate.
Between-group differences in participant characteristics at
baseline were assessed by ANOVA or chi-square test. Outliers
(±≥3.5 SD from mean) were identified and removed, with
a maximum of n = 4 outliers identified. Linear mixed-effect
models were used to assess the effectiveness of the intervention,
including “participant” as a random effect, time, and treatment
group, with the time × treatment group interaction taken as the
principal analysis of effect [as analyzed in other multidose studies
(33)]. Where significant main effects were observed, linear
combinations of coefficients between groups were explored. The
explanatory variables sex, age, change in BMI, and baseline
medication use (statin and antihypertensive medications, where
relevant) were included. Nonnormally distributed data (assessed
by the skewness–kurtosis test) were analyzed through the use of a
generalized linear model with a link log function. For lipid data, a
subgroup analysis was conducted in those not prescribed statins.
Data were analyzed with Stata version 14 (Stata Corp.)
and P and q values <0.05 were considered statistically sig-
nificant. One participant reporting ≤75% treatment compli-
ance and 1 participant with significant bodyweight increase
(+9.4 kg, 2.9 kg/m2 in 6 mo) were excluded. Completeness
of data analysis is further described in the Supplemental
Methods.
Results
In total, 115 participants completed the study (n = 37,
n = 39, n = 39; 1 cup (150 g) blueberries, 1/2 cup (75 g)
blueberries, and placebo, respectively; see Figure 1A); their
baseline characteristics are shown in Table 1. Participants were
predominantly male (68%), age range 50–75 y, BMI 31.2
kg/m2 (range: 25.8–39.6). The predominant number of MetS
criteria was 3 (53%) and 4 (40%); MetS cut-off criteria for
waist circumference, BP, TG, HDL cholesterol, and glucose
were 93%, 80%, 75%, 51%, and 27%, respectively. Statin
and antihypertensive medications were prescribed to 38% and
24%, respectively. Intervention adherencewas 94.1% compliance
across all groups (wrapper return calculations), and 82% of
respondents reported an inability to judge treatment allocation.
Dietary intake (FFQ) and physical activity did not differ between
baseline and 6 mo.
No favorable effects of the intervention were shown for
the primary endpoint HOMA-IR or indices of glucose control
[QUICKI, HbA1c (Table 2)] and peripheral, hepatic, and adipose
tissue insulin sensitivity was unchanged (confirmed by clamp
assessment in a subgroup) (Supplemental Table 4). However,
after 6 mo of 1 cup blueberries/d %FMD significantly increased
(1 cup: 1.45%; 1/2 cup: 0.00%; placebo: 0.39%; P = 0.003),
and AIx significantly reduced, compared with other treatments
(1 cup: –2.24%; 1/2 cup: 0.45%; placebo: 0.24%; P = 0.04)
(Figure 2A, B). Similarly, mean plasma cGMP concentrations
were increased following 1-cup intake (1 cup: 0.99 pmol/mL; 1/2
cup: –6.15 pmol/mL; placebo: –16.75 pmol/mL) and the time ×
treatment interaction between groups was significant (P = 0.04)
(Figure 2C). The intervention had no effect on BP (Table 2) or
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TABLE 1 Participant characteristics at baseline for the 115 adults with MetS who completed the 6-mo, multidose, freeze-dried blueberry intervention trial1
All (n = 115) Placebo (n = 39)
1/2 cup
blueberries
(n = 39)
1 cup blueberries
(n = 37)
Age, y 62.8 ± 7.1 62.9 ± 8.1 62.6 ± 7.2 63.0 ± 5.9
Gender (M), n (%) 78 (67.8) 26 (66.7) 28 (71.8) 24 (64.9)
BMI, kg/m2 31.2 ± 3.0 31.1 ± 3.0 31.2 ± 2.6 31.3 ± 3.4
HbA1c, % (mmol/mol) 5.7 ± 0.31
(39.0 ± 3.4)
5.7 ± 0.31
(38.7 ± 3.4)
5.7 ± 0.30
(39.2 ± 3.3)
5.7 ± 0.33
(39.2 ± 3.6)
Hypertension medication, n (%) 28 (24.3) 10 (25.6) 9 (23.1) 9 (24.3)
Hyperlipidemia medication, n (%) 44 (38.3) 16 (41.0) 15 (38.5) 13 (35.1)
No. of MetS criteria confirmed at screening, n (%)
3 criteria 61 (53.0) 22 (56.4) 21 (53.8) 18 (48.6)
4 criteria 46 (40.0) 16 (41.0) 16 (41.0) 14 (37.8)
5 criteria 8 (7.0) 1 (2.6) 2 (5.1) 5 (13.5)
FFQ dietary intake at baseline
Energy, kcal/d 1971 ± 555 1875 ± 517 2002 ± 595 2038 ± 551
Fat, % energy 35.1 ± 4.5 34.5 ± 5.1 35.6 ± 4.5 35.1 ± 3.9
Carbohydrate, % energy 43.0 ± 6.4 44.5 ± 5.9 41.9 ± 7.5 42.6 ± 5.4
Protein, % energy 18.5 ± 3.4 17.9 ± 3.1 18.6 ± 3.7 19.1 ± 3.5
Anthocyanins, mg/d 18.6 ± 13.6 18.6 ± 12.6 16.6 ± 14.8 20.8 ± 13.3
1Values are mean ± SD or n (%). Dietary data excluded for n = 6 considered invalid (placebo, n = 3; 1/2 cup, n = 1; 1 cup, n = 2). HbA1c data missing
for n = 1 placebo. 1 cup = 150 g blueberries. FFQ, food-frequency questionnaire; HbA1c, glycated hemoglobin; MetS, metabolic syndrome.
other biomarkers of vascular function and systemic redox status
(total free thiols) (Supplemental Table 5).
Relative to placebo, 1 cup increased HDL cholesterol levels (1
cup: + 0.04 mmol/L; placebo: –0.02 mmol/L; P = 0.03), with
a trend towards a dose-related increase (P = 0.08) (Table 2).
When statin users were excluded (n = 44; 38% of population),
a significant 0.08-mmol/L net difference in HDL cholesterol
concentrations was observed between the 1-cup group (+0.05
mmol/L) and the placebo group (–0.03 mmol/L) (P < 0.03;
Figure 3). NMR spectroscopy analysis in statin nonusers showed
that both apoA-I and HDL-P, n were significantly increased ( 0
to 6 mo) in the 1-cup group (Figure 3) compared with placebo
(P = 0.002 and P = 0.013, respectively).
The intervention had no effect on total cholesterol and LDL
cholesterol levels or the total cholesterol:HDL cholesterol ratio.
However, TG levels differed (P = 0.04; Table 2), with a
significant increase in the 1/2-cup blueberry group comparedwith
placebo (P = 0.01, Table 2); this remained when analysis was
restricted to statin nonusers (P = 0.04; Supplemental Table 6).
In further analysis in statin nonusers, NMR data showed that
neither LDL-P, n nor apoB were significantly altered following
the 1/2-cup blueberry intake (Supplemental Table 6).
In serum and 24-h urine, total concentrations of anthocyanin-
derived phenolic acid metabolites significantly increased ( 0
to 6 mo) following blueberry intake (P < 0.01 and P < 0.001,
respectively; in a dose-dependent manner, compared with
placebo) (Table 3 and Figure 2D, E). Individual metabolites
that changed were almost exclusively by-products of microbial
catabolism and human phase II metabolism (Table 3).
Discussion
In the longest-duration blueberry RCT to date, conducted in
115 adults with MetS, we report evidence for the following:
(i) 1 cup (150 g) blueberries/d for 6 mo resulted in sustained
and clinically relevant improvements in endothelial function,
systemic arterial stiffness, and HDL cholesterol concentrations
(especially in statin nonusers); (ii) increased cGMP levels, HDL
cholesterol particle density, and apoA-I levels are likely to be
underlying improvements in vascular and lipid status; and (iii)
insulin resistance and peripheral, hepatic, and adipose tissue
insulin sensitivity were unchanged by blueberry intake.
Despite finding no benefit in terms of insulin resistance, our
data demonstrate that higher intakes of blueberries (∼1 cup/d)
improved markers of vascular function and elements of lipid
status. Over 6 mo, 1 cup blueberries/d improved conduit artery
endothelial function (assessed by %FMD; effect size of 1.06%
compared with placebo) by a magnitude that translates to a 13%
reduction in future CV events based on previous meta-analyses
(34). Furthermore, we observed reduced systemic arterial stiff-
ness (assessed by AIx) and also identified improvements in HDL
cholesterol, which were most pronounced in statin nonusers.
Notably, the 3.09-mg/dL (0.08-mmol/L) difference in HDL
cholesterol between statin nonusers (when comparing 1 cup/day
with placebo) would equate to 6.2–9.3% lower risk of coronary
heart disease 11.4–14.5% lower risk of CV disease (men and
women, respectively) based on predictive data from prospective
studies (35). There has been a long-established synergy between
endothelial dysfunction and arterial stiffness (36), and between
AIx and hypercholesterolemia (37, 38), and our data identify 1
cup (150 g)/d as an effective dietary approach to reduce CV risk.
The observed increase in cGMP concentrations provides a
potential mechanistic insight into the observed cardiometabolic
effects, with a dose-dependent effect on cGMP concentrations
following blueberry/anthocyanin intake. These data suggest that
circulating cGMP levels reflect the activity status of soluble
guanylate cyclase in vascular smooth muscle coupling, which
is stimulated by endothelial NO. In support of this, previous
evidence of increased plasma cGMP following 12 wk of
purified anthocyanin extract consumption (39) adds weight to
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the suggestion that the anthocyanins may be responsible for this
effect. Contrary to our expectations, but consistent with blueberry
interventions lasting 6–8 wk (14, 18), cGMP increases were
associated neither with concomitant elevations in NO metabolite
levels (excluding the possibility of increased tonic endothelial
NO formation) nor with plasma thiol availability (indicating
no gross changes in extracellular redox status). Taken together,
this biomarker signature is consistent with an enhanced NO
bioavailability, potentially mediated by the anthocyanin-induced
increase in plasma superoxide dismutase activity, as reported
recently (40). NMR analysis also confirmed significantly in-
creased HDL particle number and apoA-I levels following 1
cup blueberries/d, which likely underpin the clinically relevant
increase in HDL cholesterol. Recently, the JUPITER study
confirmed that HDL particle number was the only predictor
of incident CV disease (41), and the China Kadoorie Biobank
prospective study established that a 1-SD increase in very
large, large, and medium HDL cholesterol particles significantly
reduced myocardial infarction risk (13% and 20% reduction
in risk), and a 1-SD increase in apoA-I reduced myocardial
infarction risk by 11% (42).
Prior to our long-term study, only acute improvements in
FMD were reported following single-dose blueberry intake
(10, 11), and only microvascular endothelial function was
improved in MetS after short-term (6-wk) blueberry intake
(16); the latter was assessed by finger tonometry, which has
been shown to be poorly correlated with CVD risk mark-
ers/atherosclerosis or FMD (43, 44). Likewise, the benefits of
blueberries on arterial stiffness were previously limited to healthy
younger adults (13) and postmenopausal women (with pre-
and stage 1 hypertension) (18), in relatively short-term studies
(6–8 wk).
Although meta-analyses of prospective cohort studies have
observed a reduced risk of diabetes with higher habitual
anthocyanin (45) or blueberry intake (46), not all of the included
studies have identified benefits (47). Similarly, RCTs to date
have not consistently supported effects on intermediate markers
associated with diabetes development, such as insulin resistance
or glucose metabolism. Despite 1 short-term study (6 wk)
showing that blueberries (668mg anthocyanins) improved insulin
sensitivity in obese patients with insulin resistance (15), others
have reported increased HbA1c and HOMA-IR following 8-wk
blueberry intake [742 mg anthocyanins (17)] in hypertensive
postmenopausal women, and no effect on insulin sensitivity
in patients with MetS (581 mg anthocyanins) (16). We found
no benefit of blueberries on any of our multi-endpoint insulin
resistance analyses, and although n = 115 completed the
study, compared with the n = 117 in our HOMA-IR power
calculation, it is considered unlikely that this would materially
affect our study findings. In our gold-standard 2-step, glucose
tracer–labeled, hyperinsulinemic euglycemic clamp we further
confirmed that peripheral, hepatic, and adipose tissue insulin
sensitivity was unaffected and there was no suppression of
hepatic glucose production and adipose tissue lipolysis. The lack
of effect in our study may relate to the high-risk participants
under investigation, with a greater likelihood of a benefit in
healthy participants. The prospective data have follow-up over
a number of years, and frequent habitual intake over the
long term may be necessary to observe a benefit on incident
disease.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/109/6/1535/5499342 by U
niversity of East Anglia user on 10 June 2019
Blueberries and cardiometabolic health 1541
(ex
cr
ete
d µ
m
o
l/2
4h
)
 
µm
o
l/2
4h
)
p<0.001
p<0.001
p<0.01p<0.001
p<0.001
P=0.04
P=0.04
P<0.001
FIGURE 2 Change in biomarkers of vascular function and total anthocyanin-derived metabolite levels in 24-h urine and serum, from baseline to 6 mo, by
intervention group. Change between 0 and 6mo is reported, by intervention group, for (A) endothelial function (%FMD); (B) arterial stiffness (AIx, standardized
at 75 bpm); (C) circulatory levels of cGMP; (D) total urinary anthocyanin-derived metabolites; and (E) total serum anthocyanin-derived metabolites. Values are
mean (95% CI). For panels A–C, values are adjusted for baseline values, age, change in BMI, sex, baseline statin intensity, and medication for hypertension.
For panels D–E, values are adjusted for sex, sample run plate, baseline BMI, change in fruit and vegetable intake, and use of medications associated with
phenolic metabolism. P values are shown for the time × treatment interaction calculated from a linear mixed-effect model. Letters indicate significant post-hoc
differences between groups; a= 1 cup compared with placebo, b= 1/2 cup compared with placebo, and c= 1 cup compared with 1/2 cup. Participant numbers:
A, 1 cup (n = 29), 1/2 cup (n = 33), placebo (n = 34); B, 1 cup (n = 35), 1/2 cup (n = 39), placebo (n = 38); C, 1 cup (n = 36), 1/2 cup (n = 38), placebo
(n = 39); D, 1 cup (n = 28), 1/2 cup (n = 27), placebo (n = 31); E, 1 cup (n = 32), 1/2 cup (n = 34), placebo (n = 37). 1 cup = 150 g blueberries. AIx@75
bpm, augmentation index standardized to 75 heart beats per minute; cGMP, cyclic guanosine monophosphate; FMD, flow-mediated dilatation.
In keeping with a meta-analysis of 6 previous blueberry
interventions, we observed no change in BP (48) and, as it is
generally accepted that aortic distensibility (PWV) is strongly
associated with peripheral BP (49), it was unsurprising that
cfPWV also remained unchanged (Table 2). Unexpectedly, we
found no benefit of a smaller daily intake of blueberries (∼1/2
cup/d, providing 182 mg anthocyanins) and, in the case of TG,
this level of blueberry intake resulted in a modest increase;
a finding contrary to a recent meta-analysis showing benefits
of short-term anthocyanin supplementation trials (45 d–24 wk)
on TG and other lipid fractions, in patients with dyslipidaemia
(50). The lack of effect in the 1/2-cup group warrants further
speculation. Although health benefits have been associated with
long-term, but modest, habitual blueberry intakes (2, 5), 1/2
cup/d for 6 mo may be insufficient to provide chronic benefits in
an obese, at-risk population. Relative to previous short-duration
blueberry RCTs (providing ∼335–742 mg anthocyanins/d) (13,
17), our daily 1/2 cup of blueberries provided lower anthocyanin
intakes (of 182 mg/d), which resulted in significantly lower
concentrations of total serum metabolites than the 1-cup group;
we reason, based on animal data showing that anthocyanin intake
profoundly affects gut microbial community structure leading
to improved biomarkers of cardiometabolic risk (51, 52), that
the lower serum metabolite concentrations and metabolite profile
variability (identified in urine) may, in part, be responsible for a
lack of an intervention effect in our 1/2-cup group.
Following ingestion, anthocyanins undergo extensive
metabolism, most of which occurs in the lower intestine.
These metabolites therefore serve as growth substrates for the
gut microbiome and likely play a key beneficial metabolic role
(53). In our study, we observed an increase in the combined total
concentration of microbially derived anthocyanin metabolites
and their human phase II conjugates, in both serum and 24-
h urine, following blueberry intake. These increases were
observed in a blueberry-dose–dependent manner and support
the high compliance with intervention in our study, further
indicated by wrapper returns. Eight metabolites in serum and
25 metabolites in 24-h urine differed significantly between
intervention groups, some of which have previously been shown
to have cardiometabolic bioactivity in animal and in vitro
studies. For example, 4-hydroxy-3,5-dimethoxybenzoic acid
(syringic acid) has increased endothelial nitric oxide synthase
expression and NO levels in cultured human endothelial cells (54,
55), whereas 3,4-dihydroxyphenylpropionic acid (dihydrocaffeic
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TABLE 3 Significant changes in anthocyanin-related metabolites and phase II conjugates in serum and urine, from baseline to 6 mo: results presented by
intervention group and concentrations presented for summed serum and urine totals, and individual metabolites and phase II conjugates1
 0 to 6 mo: placebo  0 to 6 mo: 1/2 cup  0 to 6 mo: 1 cup P
Serum metabolites,2 nmol/L n = 38 n = 34 n = 32
Total serum metabolites 325 (–1141, 1791)a 645 (–761, 2050) 3722 (2211, 5234)c <0.01
Hippuric acid –244 (–546, 57.5)a 1193 (822, 1563)b 2468 (1892, 3045)c <0.001
3/4-Methoxybenzoic acid-3/4-sulfates3 –0.16 (–3.3, 2.9)a 1.9 (–1.0, 4.9) 10.4 (7.0, 13.9)c <0.01
4-Hydroxy-3-methoxyphenylpropionic acid 1.4 (–1.7, 4.4) –2.6 (–4.8, –0.32) 5.4 (2.7, 8.1)c <0.01
2,6-Dihydroxybenzoic acid –6.0 (–14.1, 2.0) 9.4 (0.86, 18.0) –12.2 (–19.0, –5.5)c <0.01
3,4-Dihydroxycinnamic acid –3.4 (–11.0, 4.2) 7.8 (1.9, 13.6) –7.5 (–12.4, –2.7)c <0.01
2-Hydroxybenzoic acid –56.1 (–83.6, –28.6)a –22.8 (–49.5, 3.8) 15.5 (–13.8, 44.8) 0.02
3,5-Dihydroxybenzyl alcohol 2.8 (–10.6, 16.2) –22.1 (–31.3, –13.0)b –8.4 (–17.6, 0.80) 0.03
4-Hydroxy-3,5-dimethoxyphenylacetic acid 0.94 (–4.7, 6.6) 5.2 (–0.16, 10.5) –6.8 (–11.5, –2.0)c 0.03
Urine metabolites,2 μmol in 24 h n = 31 n = 27 n = 29
Total urine metabolites –300 (–928, 327)a 1593 (1007, 2179)b 1707 (1091, 2324) <0.001
Chlorogenic acid –0.07 (–0.10, –0.04)a 0.13 (0.09, 0.17)b 0.23 (0.16, 0.30) <0.001
4-Hydroxy-3,5-dimethoxybenzoic acid
(syringic acid)
–0.03 (–0.12, 0.07)a 0.41 (0.31, 0.51)b 0.74 (0.61, 0.88)c <0.001
Benzoylglutamic acid –0.10 (–0.26, 0.06)a 0.86 (0.64, 1.1)b 0.86 (0.63, 1.1) <0.001
4-Hydroxy-3-methoxybenzoic acid (vanillic
acid)
–1.6 (–2.2, –1.1)a –0.85 (–1.4, –0.31) 1.3 (0.57, 2.0)c <0.001
Hippuric acid –262 (–693, 168)a 1261 (859, 1662)b 1579 (1157, 2002) <0.001
4-Methoxybenzoic acid-3-glucuronide
(isovanillic acid-3-glucuronide)
–0.17 (–0.27, –0.08)a –0.08 (–0.15, –0.02) 0.32 (0.19, 0.45)c <0.001
2-Hydroxybenzoic acid –0.10 (–0.21, 0.01)a 0.41 (0.30, 0.53)b 0.14 (0.03, 0.25)c <0.001
4-Hydroxy-3-methoxycinnamic acid –0.07 (–0.19, 0.04)a 0.15 (0.05, 0.25)b 0.49 (0.37, 0.62)c <0.001
3,4-Dihydroxyphenylpropionic acid
(dihydrocaffeic acid)
–0.29 (–0.50, –0.09)a 0.15 (–0.10, 0.40)b 0.60 (0.34, 0.85) <0.001
Trans-3-hydroxycinnamic acid (m-coumaric
acid)
–0.04 (–0.08, 0.01)a 0.05 (0.01, 0.10)b 0.13 (0.08, 0.19) <0.001
3-Hydroxyhippuric acid –11.6 (–29.2, 6.1)a 29.3 (12.4, 46.2)b 55.6 (36.0, 75.3) <0.001
3-Hydroxy-4-methoxycinnamic acid –0.05 (–0.08, –0.02)a 0.04 (0.01, 0.06)b 0.02 (–0.01, 0.04) <0.001
3/4-Hydroxybenzoic acid-3/4-sulfates3 0.09 (–0.40, 0.59)a 1.6 (1.0, 2.2)b 2.0 (1.4, 2.6) <0.001
2,5-Dihydroxybenzoic acid –0.58 (–1.2, 0.04)a 1.2 (0.58, 1.8)b 0.94 (0.33, 1.6) <0.001
3,4-Dihydroxyphenylacetic acid –0.11 (–0.81, 0.60)a 0.72 (0.07, 1.4) 1.9 (1.2, 2.6) <0.01
3-Hydroxybenzoic acid –0.22 (–0.27, –0.16) –0.02 (–0.13, 0.10)b –0.17 (–0.22, –0.13) <0.01
3,5-Dimethoxybenzoic acid methyl ester –0.02 (–0.03, –0.01)a 0.01 (–0.01, 0.04) 0.02 (0.00, 0.03) <0.01
4-Hydroxyhippuric acid –6.1 (–15.7, 3.5)a –9.9 (–18.2, –1.7) 13.5 (3.2, 23.7)c <0.01
3-Hydroxyphenylpropionic acid 0.03 (–0.16, 0.22)a 0.34 (0.14, 0.54) 0.97 (0.58, 1.4)c <0.01
4-Hydroxy-3,5-dimethoxycinnamic acid –0.02 (–0.14, 0.11) –0.03 (–0.10, 0.04) 0.20 (0.10, 0.30)c <0.01
4-Hydroxy-3-methoxyphenylacetic acid –3.3 (–5.7, –0.97)a 2.1 (–0.46, 4.6)b 1.4 (–1.1, 4.0) 0.01
3,4-Dihydroxycinnamic acid 0.04 (–0.06, 0.14) 0.10 (0.02, 0.17) –0.09 (–0.18, 0.00)c 0.03
3,4,5-Trimethoxybenzaldehyde 0.00 (–0.01, 0.01) –0.02 (–0.03, –0.01)b 0.00 (–0.01, 0.02) 0.03
3/4-Methoxybenzoic acid-3/4-sulfates3 –0.12 (–3.0, 2.7) 6.0 (3.6, 8.4)b 1.8 (–0.42, 4.1) 0.03
4-Hydroxy-3-methoxyphenylpropionic acid –0.54 (–1.1, 0.03)a –0.46 (–0.89, –0.03) 0.60 (–0.05, 1.2) 0.03
1Values are mean (95% CI) adjusted for sex, sample run plate, baseline BMI, change in fruit and vegetable intake, and use of medications associated
with phenolic metabolism. Cup indicates the equivalent number of US cups of fresh blueberries. Outliers < or >3.5 SD were excluded. P is the false
discovery rate–adjusted value for the time × treatment interaction calculated with the use of a linear mixed-effect model; only significant metabolites are
shown; letters indicate significant differences between groups: a = 1 cup compared with placebo, b = 1/2 cup compared with placebo, and c = 1 cup
compared with 1/2 cup (based on false discovery rate–adjusted P values). 1 cup = 150 g blueberries.
2Across urine and serum analysis, a maximum of n = 3 outliers were identified in any metabolite assessment.
3Where two compounds are reported together, they could not be sufficiently resolved.
acid) and 4-hydroxy-3-methoxybenzoic acid (vanillic acid) levels
were associated with improved cardiometabolic health in animal
models of hypercholesterolemia (56) and hypertension (57).
Human data are now required to understand the contribution
of individual metabolites, or combinations of metabolites
(“metabolic signatures”), to cardiometabolic health.
The long duration of our intervention is a particular strength
as our study data have narrowed the gap in understanding
between previous acute (10, 11) and short-term RCTs (13, 16–
18) and the extensive prospective data which show that higher
habitual intakes of blueberries/anthocyanins reduce CVD risk (2,
4, 5, 8). Our selection of participants with MetS addresses an
underrepresented at-risk population and our use of an extensive
range of gold-standard methodologies (i.e., FMD and clamp),
supported by highly specific NO/redox biomarkers and NMR
lipid analyses, has robustly assessed the effectiveness of the
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p=0.002
FIGURE 3 Changes in HDL cholesterol, HDL particle number and
apoA-I levels from baseline to 6 mo by statin nonusers (n = 71), by
intervention group. Change between 0 and 6 mo, reported by intervention
group, for levels of HDL cholesterol (mmol/L) and apoA-I (g/L) and the
number of HDL particles (×10–6) in volunteers withMetS, and not medicated
with statins, after 6-mo daily intake of 1/2 or 1 cup (75 g or 150 g) blueberries
or matched placebo. Values are mean (95% CI), adjusted for baseline values,
age, change in weight, sex. P values are shown for the time × treatment
interaction calculated from a linear mixed-effect model. Letters indicate
significant differences between groups: a = 1 cup compared with placebo,
b = 1/2 cup compared with placebo and c = 1 cup compared with 1/2 cup.
Participant numbers: 1 cup (n= 24), 1/2 cup (n= 23), placebo (n= 24); n= 1
outlier excluded (1 cup group) for apoA-I analysis. apoA-I, apolipoprotein A-
I; MetS, metabolic syndrome.
intervention. A potential limitation is that despite an open
recruitment policy, our population was predominantly white and
those with confirmed MetS (at screening) were predominantly
men, reducing our ability to establish whether these data translate
to other ethnicities and if gender disparities exist.
In conclusion, we present what we believe to be the first longer-
term evidence of clinically relevant improvements in endothelial
function and systemic arterial stiffness, following blueberry
intake, in an at-risk population with MetS; most likely due to
improvements in NO bioactivity and lipid status. The simple and
attainable message to consume 1 cup of blueberries daily should
be given to those aiming to improve their CV health.
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